Portal de Periódicos da CAPES

Diagnostic Potential of Serum Proteomic Patterns in Prostate Cancer

2003; Lippincott Williams & Wilkins; Volume: 170; Issue: 2 Linguagem: Inglês

10.1097/01.ju.0000069431.95404.56

1527-3792

Lionel L. Bañez, P Prasanna, Leon Sun, Amina Ali, Zhiqiang Zou, Bao-Ling Adam, David G. McLeod, Judd W. Moul, Shiv Srivastava,

Molecular Biology Techniques and Applications

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Aug 2003Diagnostic Potential of Serum Proteomic Patterns in Prostate Cancer LIONEL L. BAÑEZ, PREMKALA PRASANNA, LEON SUN, AMINA ALI, ZHIQIANG ZOU, BAO-LING ADAM, DAVID G. McLEOD, JUDD W. MOUL, and SHIV SRIVASTAVA LIONEL L. BAÑEZLIONEL L. BAÑEZ Equal study contribution. More articles by this author , PREMKALA PRASANNAPREMKALA PRASANNA Equal study contribution. More articles by this author , LEON SUNLEON SUN More articles by this author , AMINA ALIAMINA ALI More articles by this author , ZHIQIANG ZOUZHIQIANG ZOU More articles by this author , BAO-LING ADAMBAO-LING ADAM More articles by this author , DAVID G. McLEODDAVID G. McLEOD Financial interest and/or other relationship with Astra Zeneca. More articles by this author , JUDD W. MOULJUDD W. MOUL Financial interest and/or other relationship with Astra Zeneca, ICPME, Metastatin Pharmaceuticals and Quintiles. More articles by this author , and SHIV SRIVASTAVASHIV SRIVASTAVA More articles by this author View All Author Informationhttps://doi.org/10.1097/01.ju.0000069431.95404.56AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: The serum prostate specific antigen test has been widely used in the last decade as an effective screening tool for prostate cancer (CaP). However, the high false-positive rate of the serum prostate specific antigen test necessitates the development of more accurate diagnostic and prognostic biomarkers for CaP. Promising diagnostic potential of serum protein patterns detected by surface enhanced laser desorption/ionization time of flight mass spectrometry for CaP has recently been reported. Independent evaluation of this new technology is warranted to realize its translational utility. We determined whether serum protein profiling by surface enhanced laser desorption/ionization time of flight mass spectrometry and a decision tree algorithm classification system could accurately discriminate between patients with CaP and unaffected individuals. Materials and Methods: Proteomic spectra of crude serum were generated using the Ciphergen ProteinChip System and pattern detection was performed using Biomarker Patterns Software (Ciphergen Biosystems, Inc., Fremont, California). A total of 106 patients with CaP and 56 controls were randomly allocated to a training set and a test set. The training set, which consisted of 44 patients with cancer and 30 controls, was used to build a decision tree algorithm. The test set, which consisted of 62 patients with cancer and 26 controls, was used in blinded fashion to validate the decision tree. Results: Accuracy of classification using the test set was 67% and 42% for the weak cation exchange array and the copper metal affinity capture array, respectively. Combined spectral data from the weak cation exchange and copper metal affinity capture arrays generated an algorithm that achieved 85% sensitivity and 85% specificity for the detection of CaP. Conclusions: These preliminary findings support recent observations that complex protein profiles have promising potential for the early detection of CaP and warrant future studies with streamlined technology. Furthermore, the combined effect of using 2 array types can greatly enhance the ability of protein profile patterns, suggesting the potential usefulness of alternative approaches to evaluate this new emerging technology. References 1 : Cancer Statistics, 2002. CA Cancer J Clin2002; 52: 23. Crossref, Medline, Google Scholar 2 : Clinical practice. Prostate-specific antigen testing for early diagnosis of prostate cancer. N Engl J Med2001; 344: 1373. Google Scholar 3 Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology2000; 14: 267. Medline, Google Scholar 4 : Cancer genomics. Cancer Cell2002; 1: 37. Google Scholar 5 : DNA microarrays in clinical oncology. J Clin Oncol2002; 20: 1932. Google Scholar 6 : Differential screening and mapping of proteins from premalignant and cancer cell lines using nonporous reverse-phase HPLC coupled with mass spectrometric analysis. Anal Chem2001; 73: 1219. Google Scholar 7 : Protein profiles in sera of patients with malignant cutaneous melanoma. Rapid Commun Mass Spectrom2000; 14: 1149. Google Scholar 8 : Tandem mass spectrometry methods for definitive protein identification in proteomics research. Electrophoresis2000; 21: 2252. Google Scholar 9 : Mass spectrometry meets chip technology: a new proteomic tool in cancer research?. Electrophoresis2001; 22: 2898. Google Scholar 10 : Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol2001; 158: 1491. Google Scholar 11 : Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. Clin Cancer Res2002; 8: 2541. Google Scholar 12 : Use of proteomic patterns in serum to identify ovarian cancer. Lancet2002; 359: 572. Google Scholar 13 : Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res2002; 62: 3609. Google Scholar 14 : Classification and Regression Trees. Belmont, California: Wadsworth Publishing Co., Inc.1984. Google Scholar 15 : Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem2002; 48: 1296. Google Scholar 16 : Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst2002; 94: 1576. Google Scholar 17 : DNA microarray analysis of complex biologic processes. J Am Soc Nephrol2001; 12: 1072. Google Scholar 18 : A review of evidence of health benefit from artificial neural networks in medical intervention. Neural Netw2002; 15: 11. Google Scholar 19 : How good are support vector machines?. Neural Netw2000; 13: 17. Google Scholar From the Center for Prostate Disease Research, Department of Surgery, Uniformed Services University of the Health Sciences (LLB, PP, LS, AA, ZZ, JWM, SS), Bethesda, Maryland, Department of Microbiology and Molecular Cell Biology, Eastern Virginia Medical School (B-LA), Norfolk, Virginia, and Urology Service, Walter Reed Army Medical Center (DGM, JWM), Washington, D. C.© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byMOBLEY J, LAM Y, LAU K, PAIS V, L’ESPERANCE J, STEADMAN B, FUSTER L, BLUTE R, TAPLIN M and HO S (2018) MONITORING THE SEROLOGICAL PROTEOME: THE LATEST MODALITY IN PROSTATE CANCER DETECTIONJournal of Urology, VOL. 172, NO. 1, (331-337), Online publication date: 1-Jul-2004.LI J, WHITE N, ZHANG Z, ROSENZWEIG J, MANGOLD L, PARTIN A and CHAN D (2018) Detection of Prostate Cancer Using Serum Proteomics Pattern in a Histologically Confirmed PopulationJournal of Urology, VOL. 171, NO. 5, (1782-1787), Online publication date: 1-May-2004. Volume 170Issue 2August 2003Page: 442-446 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.Keywordsprostateprostatic neoplasmsproteomicsproteinsspectrometry, mass, matrix-assisted laser desorption-ionizationMetricsAuthor Information LIONEL L. BAÑEZ Equal study contribution. More articles by this author PREMKALA PRASANNA Equal study contribution. More articles by this author LEON SUN More articles by this author AMINA ALI More articles by this author ZHIQIANG ZOU More articles by this author BAO-LING ADAM More articles by this author DAVID G. McLEOD Financial interest and/or other relationship with Astra Zeneca. More articles by this author JUDD W. MOUL Financial interest and/or other relationship with Astra Zeneca, ICPME, Metastatin Pharmaceuticals and Quintiles. More articles by this author SHIV SRIVASTAVA More articles by this author Expand All Advertisement PDF downloadLoading ...